Kojima S, Awaya A, Ishido M, Koyama Y, Kubodera A, Hashimoto Y, Fukui H, Muramatsu H, Muramatsu T
Research Institute for Biosciences, Science University of Tokyo, Noda-shi, Japan.
J Cancer Res Clin Oncol. 1990;116(4):336-40. doi: 10.1007/BF01612915.
The in vivo localization of a polyclonal antibody (pAb) against a glycoprotein with a molecular mass of 68 kDa (GP68), which was found in developing mouse brain, was studied in murine tumor models to evaluate potential applications of this antibody for in vivo radioimmunodetection and/or therapy of cancer. The tissue distribution of 125I-labeled GP68 pAb 3 days after i.v. injection into mice bearing four different kinds of solid tumor revealed a high uptake ratio by adenocarcinoma 755 and Lewis 3LL lung cancer. In contrast, the uptake ratio was low in mice bearing Ehrlich solid tumor and sarcoma-180 (S-180). These uptake ratios accorded well with the in vitro binding activity of this antibody with the tumor cells. In an immunoscintigraphic study, adenocarcinoma 755 was successfully visualized with 67Ga-labeled GP68 pAb. The results of these biodistribution and in vivo radioimmunoscintigraphic studies suggest that GP68 antibody may be applicable to the diagnosis and/or therapy of cancer.
在发育中的小鼠大脑中发现了一种针对分子量为68 kDa的糖蛋白(GP68)的多克隆抗体(pAb),在鼠类肿瘤模型中研究了其体内定位,以评估该抗体在癌症体内放射免疫检测和/或治疗中的潜在应用。静脉注射到患有四种不同实体瘤的小鼠体内3天后,125I标记的GP68 pAb的组织分布显示腺癌755和Lewis 3LL肺癌的摄取率很高。相比之下,在患有艾氏实体瘤和肉瘤-180(S-180)的小鼠中摄取率较低。这些摄取率与该抗体与肿瘤细胞的体外结合活性非常吻合。在免疫闪烁显像研究中,用67Ga标记的GP68 pAb成功地显示出腺癌755。这些生物分布和体内放射免疫闪烁显像研究的结果表明,GP68抗体可能适用于癌症的诊断和/或治疗。